Jeff Schaal

Jeff Schaal has extensive work experience in the field of radiopharmaceuticals and biomedical engineering. Jeff currently serves as the Senior Vice President at Solve Therapeutics, Inc., leading the Theragnostic R&D division and focusing on developing targeted radiopharmaceuticals in the field of oncology. Jeff utilizes a proprietary radiolabeling platform and chemistry methods to deliver precision nuclear medicine and develop radionuclide therapeutics and companion diagnostics.

Prior to joining Solve Therapeutics, Inc., Jeff was the Chief Scientific Officer at Cereius, Inc., where they led the research and development efforts to advance the company's radiopharmaceutical asset portfolio and proprietary radiochemistry linker platform. Jeff also played a key role in the acquisition of Cereius, Inc. by Solve Therapeutics, Inc. Before their role as Chief Scientific Officer, Jeff was the Director of Research at Cereius, Inc., leading the R&D efforts of a start-up focused on developing targeted, radionuclide therapeutics for metastatic brain cancer detection and treatment.

Jeff's academic background includes a Ph.D. in Biomedical Engineering from Duke University, where they developed technology utilizing thermally-responsive biopolymers for stable delivery of loco-regional radionuclide therapy for solid cancers. Their research also demonstrated the technology's potential to synergistically interact with traditional chemotherapy agents to overcome resistance mechanisms in pancreatic cancer. Jeff also holds a Master of Science degree in Biomedical Engineering from Duke University.

Prior to their academic pursuits, Jeff worked as a Business Technology Consultant at Deloitte Consulting, LLP, where they collaborated with Fortune 500 companies to solve business problems, develop strategies, and improve operational processes. Jeff also has experience as a Wet Process Engineer Intern at Micron Technology, where they chemically treated semiconductors and conducted research to improve tool performance. Additionally, Jeff completed an internship as an Analyst with Science Applications International Corporation - TRSC, where they worked with the federal Defense Threat Reduction Agency to reduce and eliminate weapons of mass destruction.

During their undergraduate years at the University of Notre Dame, Jeff served as a Resident Assistant in the Office of Residential Life and worked as a Sports Information Student Worker, providing support for NCAA Division IA sporting events.

Throughout their career, Jeff has demonstrated expertise in radiopharmaceuticals, biomedical engineering, research and development, business consulting, and project management.

Jeff Schaal received their Bachelor of Science degree in Chemical Engineering from the University of Notre Dame in the years 2002 to 2006. Jeff then pursued a Master of Science degree in Biomedical Engineering at Duke University from 2010 to 2012. Following this, Jeff completed their education at Duke University by obtaining a Doctor of Philosophy (PhD) in Biomedical Engineering between 2013 and 2018.